NASDAQHealth CareMedical Instruments & SuppliesSnapshot 2026-07-31
Reading ISRG? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care Equipment: fringe margins under pressure (3q confirmed)
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar broken — Grow da Vinci procedures about 16% YoY: procedure growth not reported vs 16%.
View ThesisRevenue is growing steadily — about 21% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 15%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins, the balance sheet.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskIntuitive Surgical's growth in da Vinci procedures must continue to justify its current valuation. Revenue grew 19% year over year in the latest quarter, and the company beat earnings estimates by 18.5%. It trades at 36× P/E versus a peer median of 33×, indicating that the price reflects less growth than forecasted. The primary risk is that procedure growth has not been reported as expected, with a 15% probability of missing outlook in the next quarter. Peer multiples imply a price roughly in line with where it trades. This read is provisional.
Trailing returns as of 2026-07-31. ISRG is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 36 analysts currently covering ISRG (as of Jul 2026).
Based on 16 Wall Street analysts offering 12-month price targets for ISRG in the last 4 months.
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-08-01. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Equipment — fair value, gap to price, and forward P/E.
Potential changes in ACA could impact procedure volume.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-31. EPS is implied from price ÷ P/E. Not investment advice.
Current $353.33
The last 12 months of price, then the range of analyst 12-month targets from today’s $353.33.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
J&J's actions may impact ISRG's market position.
Threatens: Increase da Vinci procedure volume
J&J's approval poses competitive threat to da Vinci procedures.
Threatens: Increase da Vinci procedure volume
Concerns about U.S. growth could impact procedure volume.
Threatens: Increase da Vinci procedures
Growth concerns may hinder da Vinci procedure increases.
Threatens: Increase da Vinci procedures
Obamacare concerns could impact medtech demand negatively.
Threatens: Increase da Vinci procedures
Obamacare concerns could impact medtech demand negatively.
Advances: Increase da Vinci procedures
Strong demand indicates growth in da Vinci procedures.
